Home › NDC Lookup › RxCUI directory › RxCUI 2717197

Lenacapavir 300 MG Oral Tablet [Yeztugo] — RxCUI 2717197

RxNorm drug concept · Semantic branded drug
RxCUI 2717197 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2717197
Official nameLenacapavir 300 MG Oral Tablet [Yeztugo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asYeztugo 300 MG (as lenacapavir sodium 306.8 MG) Oral Tablet; Yeztugo 300 MG Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)2,802 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lenacapavir Oral: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Lenacapavir works by targeting the HIV virus's outer protein shell — called the capsid — which disrupts its ability to replicate. The oral tablets serve a specific purpose at the s...
  • What exactly does lenacapavir do, and why do I need the tablets if there's also an injection?
  • Yes, absolutely — this is one of the most important things to know. You must be tested for HIV-1 before every single injection using a sensitive FDA-approved test, not just when yo...
  • I'm taking Yeztugo to prevent HIV — do I still need to get tested regularly?
📖 Read our full Lenacapavir Oral guide →

🕸️ Concept Web — How Lenacapavir 300 MG Oral Tablet [Yeztugo] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lenacapavir 300 MG Oral Tablet [Yeztugo] RxCUI 2717197

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lenacapavir 2625651
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Yeztugo 2717192
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lenacapavir Oral Tablet 2625889
    • Lenacapavir Oral Product 2625887
    • Lenacapavir Pill 2625888
    • Lenacapavir Oral Tablet [Yeztugo] 2717196
    • Yeztugo Oral Product 2717194
    • Yeztugo Pill 2717195
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 2

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Lenacapavir 300 MG [Yeztugo] SBDC · 2717193
  • Lenacapavir Oral Tablet [Yeztugo] SBDF · 2717196
  • Yeztugo Oral Product SBDG · 2717194
  • Yeztugo Pill SBDG · 2717195
  • Yeztugo BN · 2717192

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2717197 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61958-3401-01 4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3401-1) Yeztugo Gilead Sciences, Inc. 2025-06-18
61958-3402-01 1 KIT in 1 CARTON (61958-3402-1) * 1.5 mL in 1 VIAL (61958... Yeztugo Gilead Sciences, Inc. 2025-06-18
Observed labelers: Gilead Sciences, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.